A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.
Key facts
- Study ID
- NCT06804824
- Run by
- Vividion Therapeutics, Inc.
- People needed
- 220
- Starts
- 2025-02-25
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2026-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- START Mid West — Grand Rapids, Michigan, United States (enrolling)
- NEXT Austin — Austin, Texas, United States (enrolling)
- NEXT Dallas — Irving, Texas, United States (enrolling)
- START San Antonio — San Antonio, Texas, United States (enrolling)
- NEXT San Antonio — San Antonio, Texas, United States (enrolling)
- START Mountain — Ogden, Utah, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- Clinical Research South Australia (CRSA) — Adelaide, South Australia, Australia (enrolling)
- Linear Clinical — Nedlands, Western Australia, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.